2026-01-28 - Analysis Report
**Summary Report for Abbott Laboratories (ABT)**

### Company Overview
Abbott Laboratories is a multinational American healthcare company that specializes in the development of medical devices, pharmaceuticals, and nutritional products.

### 1. Return Rate Comparison
**Cumulative Return of Review Stock:** 55.09%
**Cumulative Return of Comparison Stock (S&P 500, VOO):** 128.51%
**Divergence:** -71.80 (current), 0.50% (relative divergence)
* The review stock has a lower cumulative return compared to the S&P 500.
* The current divergence is close to the minimum value (-72.50) in the given range.

### 2. Recent Stock Price Fluctuations
**5-day, 20-day, 60-day Moving Average Figures:**
* Close: $108.27
* Last-market: $108.27 (previousClose: $108.77, change: -0.46)
* 5-day SMA: $110.76
* 20-day SMA: $121.37
* 60-day SMA: $124.51
* The review stock has seen a slight price drop in the last market session.

### 3. RSI, PPO, and Delta_Previous_Relative_Divergence Analysis
**Market Risk Indicator (MRI)]:** 0.70
**RSI:** 8.68
**PPO:** -1.61
**Hybrid Signal:** Buy (Cash 0%)
**Recent Relative Divergence Change:** 0.50 (+): improving
**7-day Rank Change:** 13 (+): rank up
**7-day Dynamic Expected Return Change:** 878.80 (+): improving
**Expected Return (%):** -722.00%
* The hybrid signal suggests a buy recommendation.
* The review stock has shown an improving trend in relative divergence and dynamic expected return.
* The expected return is significantly low, indicating a high risk associated with the investment.

### 4. Recent News & Significant Events
Several news articles have been reported recently, indicating a potential pullback in Abbott's stock. Key headlines include:

* Abbott Dives 7% On Quarterly Upset As Exact Close Looms
* Why Abbott Laboratories Shares Are Sliding Today
* Is The Fall In Abbott Stock Justified?
* Insider Purchase: CHAIRMAN AND CEO of $ABT Buys 18,800 Shares
* ABT Earnings: Abbott Stock Sinks as Profit Hit Takes Shine Off Sales Growth
* Is Abbottâ€™s January Pullback a Good Time to Buy?
* These articles suggest that the review stock has encountered some recent issues, which may affect its performance in the short term.

### 4-2. Analyst Opinions
**Analyst Consensus:**
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.79 (~Buy)
* Opinions: 24
* Target Price (avg/high/low): $136.32 / $169.00 / $115.00
* Analysts are generally optimistic about the review stock, recommending a buy with an average target price of $136.32.

### 5. Recent Earnings Analysis
**Earnings Data:**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | 0.94 | $11.37 B$ |
| 2025-07-30 | 1.02 | $11.14 B$ |
| 2025-04-30 | 0.76 | $10.36 B$ |
| 2024-10-31 | 0.94 | $10.63 B$ |
| 2025-10-29 | 0.94 | $10.63 B$ |
* The review stock has reported stable earnings in recent quarters, with a slight increase in the latest quarter.

### 6. Financial Information
**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
* The review stock has shown a relatively stable revenue trend in recent quarters, with a slight increase in profit margin.
**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
* The review stock has shown a relatively stable equity trend in recent quarters, with a fluctuating ROE.

### 7. Comprehensive Analysis
The review stock has shown a stable earnings trend in recent quarters, with a slight increase in the latest quarter. However, the stock has encountered some recent issues, which may affect its performance in the short term. Analysts are generally optimistic about the stock, recommending a buy with an average target price of $136.32. The stock has a low expected return, indicating a high risk associated with the investment.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.